Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03215173
Other study ID # 17-0045
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 1, 2017
Est. completion date November 30, 2020

Study information

Verified date March 2021
Source University of Colorado, Denver
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study plans to learn more about how to increase postpartum weight loss and how to decrease risk factors for postpartum women at increased risk for diabetes and heart disease. The program is delivered using a mobile application (app) and a lifestyle coach. This mobile application is developed for women who are at higher risk for diabetes and heart disease. Women who have gestational diabetes, (diabetes during pregnancy, or GDM), gestational hypertension (high blood pressure), and/or preeclampsia (high blood pressure and protein in the urine), and/or small-for gestational-age, and/or preterm (early) delivery during their pregnancies have a higher risk for diabetes and heart disease. This mobile application was developed using the latest research studies and using the evidence-based Diabetes Prevention and Colorado Weigh programs. The goal of the program is to help women lose weight and participate in physical activity after delivery.


Recruitment information / eligibility

Status Completed
Enrollment 82
Est. completion date November 30, 2020
Est. primary completion date November 30, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: 1. Age 18-45 2. Postpartum Body Mass Index (BMI): 26- 45 kg/m2 (=24 for Asians) 3. Positive history of one or more of the following complications in most recent singleton or twin pregnancy: 1. Gestational diabetes mellitus (by Carpenter-Coustan criteria, IADPSG (International Association of the Diabetes and Pregnancy Study Groups) criteria, or a documented clinical diagnosis). Women with a glucose value >200 mg/dL after a 50-g glucose challenge test at >12 weeks gestation will also be included. 2. Preeclampsia (high blood pressure and proteinuria diagnosed after 20 weeks gestation) 3. Gestational hypertension (new hypertension diagnosed after 20 weeks without proteinuria) 4. Pre-term delivery (32-37 weeks) 5. Small for gestational age (<10th percentile for gestational age) 4. Access to and be willing to use a wi-fi enabled iPhone (5 or higher) or iPod (5 or higher). 5. Capable of providing informed consent 6. Between 4 weeks and 16 weeks after delivery Exclusion criteria include: 1. Personal history of Type 1 or 2 diabetes 2. Personal history of breast cancer or any other type of cancer other than a basal cell skin cancer; 3. Personal history of major chronic illness all to be assessed by the study physician for ability to participate, including: 1. cardiovascular disease (coronary artery disease, congestive heart failure, valvular heart disease, stroke, transient ischemic attack, or intermittent claudication), 2. kidney disease affecting kidney function severe enough to affect participation, 3. liver disease affecting liver function severely enough to affect participation, 4. venous or arterial thromboembolic disease, 5. untreated adrenal insufficiency, 6. depression requiring hospitalization within the past 6 months, or 7. non-pregnancy related illness requiring overnight hospitalization in the past 6 months; 4. Underlying disease/treatment that might interfere with participation in/completion of the study (e.g. significant gastrointestinal conditions, major psychiatric disorders affecting the ability to participate, and others at the discretion of the study clinician); 5. Re-current pregnancy; 6. Diagnosis of diseases associated with glucose metabolism; 7. Current or planned participation in a commercial weight loss program (i.e. Jenny Craig) over the duration of the study; 8. Previous or planned bariatric surgery; 9. Taking certain prescription medications including 1. high dose glucocorticoids, 2. atypical antipsychotics associated with weight gain (such as risperdal (risperidone), clozapine (clozaril), olanzapine (zyprexa), quetiapine (seroquel), etc.) or 3. weight loss medications including prescription (Qsymia, phentermine, topiramate, Belviq, Contrave, Saxenda, Orlistat), or non-prescription (Alli) medications; 10. Taking metformin or other medications known to affect glucose metabolism; 11. Other active medical problems detected by examination or laboratory testing, at the discretion of the physician; 12. Any fasting blood glucose > 126 mg/dl, any HbA1c at or above 6.5%, or any plasma glucose >200 mg/dl during the first trimester.

Study Design


Intervention

Behavioral:
Fit After Baby
Mobile application
Text4Baby Control Group
Receive free text messages

Locations

Country Name City State
United States University of Colorado Aurora Colorado

Sponsors (1)

Lead Sponsor Collaborator
University of Colorado, Denver

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in weight loss from baseline to one year postpartum Documentation of any change in weight at one year postpartum compared to weight at baseline, 6 weeks, 6 months and 12 months Baseline (~6 weeks), 6 months, and 12 months
Primary Change in postpartum weight retention Documentation of any change in postpartum weight at one year postpartum compared to pre-pregnancy weight at 6 weeks, 6 months and 12 months Pre-pregnancy, 6 weeks, 6 months, and 12 months
Secondary Evaluation of Subject Satisfaction Subject satisfaction will be documented using a Likert scale Weekly from Baseline (~6 weeks) to 18 weeks postpartum and then at 6 months and 12 months postpartum
Secondary Adherence to self monitoring Frequency Daily from Baseline to 18 weeks postpartum and then at 6 months and 12 months postpartum
Secondary Use of app Frequency Daily from Baseline to 12 months postpartum
Secondary Number of interactions with lifestyle coach Number Daily from Baseline to 12 months postpartum
Secondary Change in waist circumference Change in cm Baseline to 6 months and to 12 months
Secondary Change in fasting glucose Change in mg/dL Baseline to 6 months and to 12 months
Secondary Change in HbA1c Change in % Baseline to 6 months and to 12 months
Secondary Change in fasting insulin Change in fasting insulin Baseline to 6 months and to 12 months
Secondary Change in adiponectin Change in adiponectin Baseline to 6 months and to 12 months
Secondary Change in lipids HDL, LDL, Triglycerides Baseline to 6 months and to 12 months
Secondary Change in blood pressure Change in mmHg Baseline to 6 months and to 12 months
Secondary Change in hsCRP Change in hsCRP Baseline to 6 months and to 12 months
Secondary Change in postnatal depression score Edinburgh Postnatal Depression Scale Baseline to 6 months and to 12 months
Secondary Change in Physical activity Modified Pregnancy Physical Activity Questionnaire (PPAQ) Baseline to 6 months and to 12 months
Secondary Change in Social Support Social Support for Eating Habits Survey; Social Support for Physical Activity Baseline to 6 months and to 12 months
Secondary Change in Self-Efficacy Self Efficacy Survey for Diet and Exercise Behaviors Baseline to 6 months and to 12 months
Secondary Change in Perceived Stress Perceived Stress Scale Baseline to 6 months and to 12 months
Secondary Change in dietary intake 2005 Block FFQ Baseline to 6 months and to 12 months
Secondary Change in breastfeeding status Breastfeeding frequency and intensity Baseline to 6 months and to 12 months
Secondary Change in Readiness to Change Readiness to Change Questionnaire Baseline to 6 months and to 12 months
See also
  Status Clinical Trial Phase
Completed NCT05594446 - Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
Completed NCT03975309 - DHS MIND Metabolomics
Completed NCT01855399 - Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes N/A
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Recruiting NCT05007990 - Caregiving Networks Across Disease Context and the Life Course
Active, not recruiting NCT04420936 - Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program N/A
Recruiting NCT03549559 - Imaging Histone Deacetylase in the Heart N/A
Completed NCT04903496 - Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
Completed NCT01437592 - Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects Phase 1
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT03390179 - Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Recruiting NCT05294822 - Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes N/A
Completed NCT04427982 - Dance and Diabetes/Prediabetes Self-Management N/A
Completed NCT02356848 - STEP UP to Avert Amputation in Diabetes N/A
Completed NCT03292185 - A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects Phase 1
Active, not recruiting NCT05477368 - Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes N/A
Completed NCT04496401 - PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus Phase 4